Cronos Group Past Earnings Performance

Past criteria checks 0/6

Cronos Group's earnings have been declining at an average annual rate of -58.5%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 25% per year.

Key information

-58.5%

Earnings growth rate

-62.8%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate25.0%
Return on equity-4.3%
Net Margin-42.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Cronos Group Is Probably Undervalued As Liquidity Swells

Dec 05

Buy Cronos Stock Before It Surges Higher

Aug 20

Cronos Group: An Intriguing Value Opportunity

Jun 17

Cronos Stock: Attractive Now With Cannabis Legalization In Germany

Mar 04

Cronos Group: Flush With Cash And Trading Below Book Value

Feb 11

Cronos Group GAAP EPS of -$0.05 beats by $0.01, revenue of $23.1M misses by $5.25M

Aug 09

Cronos Group: Too Much Cash, Too Soon - Making The Bear Case

Aug 01

Cronos Group: High Hurdles

May 11

Cronos Earnings: Cannabis Stock With 65% Net Cash And 51% Revenue Growth

Mar 01

Cronos Group Late-Filed Q3-2021 Earnings Show Revenues From Synthetic Cannabinoids

Feb 22

Cronos Group: Still No Reason To Own

Jan 22

Cronos Group Strategic Investor Altria May Be About To Buy The Balance

Nov 08

After Cronos Finally Invests In U.S. Cannabis, Is The Stock A Buy?

Aug 30

Is Cronos Stock Worth Buying? Probably, But Patience Remains A Requirement

Jul 12

Cronos Group stock rises 2.6% with acquisition of 10.5% stake in PharmaCann

Jun 14

Cronos Group: Still Hasn't Launched

May 09

Cronos Group Q1 Earnings Preview

May 06

Cronos: The Most Confusing Cannabis Stock

Apr 28

Cronos: Sitting On Your Hands Is Not A Winning Strategy

Jan 03

Cronos Group (CRON) Investor Presentation - Slideshow

Nov 24

Cronos Is A Buy With Increasing Revenues

Nov 18

Cronos shares rise 5% on solid Q3 beat; top-line +96% boosted by advancement in Canadian/Israeli market

Nov 05

Cronos: Failure To Launch

Nov 03

Revenue & Expenses Breakdown

How Cronos Group makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:CRON Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24111-48745
30 Jun 24102-57755
31 Mar 2493-54775
31 Dec 2387-70816
30 Sep 2385-101877
30 Jun 2381-133918
31 Mar 2384-1459311
31 Dec 2287-15510113
30 Sep 2291-21310917
30 Jun 2291-10213021
31 Mar 2285-26314522
31 Dec 2165-12712222
30 Sep 2166-37315424
30 Jun 2157-38114222
31 Mar 2151-31013221
31 Dec 2047-7213020
30 Sep 203710112619
30 Jun 203163611617
31 Mar 202992910716
31 Dec 19241,16711612
30 Sep 19211,089658
30 Jun 1918479465
31 Mar 1913293323
31 Dec 1812-21242
30 Sep 189-8150
30 Jun 187-1110
31 Mar 185-290
31 Dec 173-170
30 Sep 174160
30 Jun 172050
31 Mar 171-140
31 Dec 160-130
30 Sep 162020
30 Jun 162010
31 Mar 163110
31 Dec 152010
30 Sep 150-420
30 Jun 15-1-420
31 Mar 15-1-420
31 Dec 14-1-420
30 Sep 140-210
30 Jun 140-110

Quality Earnings: CRON is currently unprofitable.

Growing Profit Margin: CRON is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CRON is unprofitable, and losses have increased over the past 5 years at a rate of 58.5% per year.

Accelerating Growth: Unable to compare CRON's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CRON is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (42%).


Return on Equity

High ROE: CRON has a negative Return on Equity (-4.34%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 02:17
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cronos Group Inc. is covered by 19 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vahan AjamianBeacon Securities Limited
Tamy ChenBMO Capital Markets Equity Research
Lisa LewandowskiBofA Global Research